Clinical Research Directory
Browse clinical research sites, groups, and studies.
To Evaluate the Efficacy and Safety of Co-administrated HODO-2224-1 and HODO-2224-2 in Patients With Essential Hypertension and Primary Hypercholesterolemia
Sponsor: Hyundai Pharm
Summary
A Multicenter, Randomized, Double-blind, Active-controlled, Parallel group, Phase 3 trial to Evaluate the Efficacy and Safety of Co-administrated HODO-2224-1 and HODO-2224-2 in Patients with Essential Hypertension and Primary Hypercholesterolemia
Official title: A Multicenter, Randomized, Double-blind, Active-controlled, Parallel Group, Phase 3 Trial to Evaluate the Efficacy and Safety of Co-administrated HODO-2224-1 and HODO-2224-2 in Patients With Essential Hypertension and Primary Hypercholesterolemia
Key Details
Gender
All
Age Range
19 Years - Any
Study Type
INTERVENTIONAL
Enrollment
125
Start Date
2025-04-22
Completion Date
2028-12-31
Last Updated
2025-05-22
Healthy Volunteers
No
Interventions
Ezetimibe/Rosuvastatin/Candesartan/Amlodipine
PO, QD, 8 weeks
Candesartan/Amlodipine
PO, QD, 8 weeks
Candesartan/Rosuvastatin/Ezetimibe
PO, QD, 8 weeks
Locations (1)
Hanyang University Hospital
Seoul, South Korea